Inflammasomes and Obesity
tuo deng,jun cui,christopher j lyon,nan zhang,h y wang,rongfu wang,willa a hsueh
DOI: https://doi.org/10.1007/978-1-4614-6819-6_2
2013-01-01
Abstract:A.J. Dannenberg and N.A. Berger (eds.), Obesity, Infl ammation and Cancer, Energy Balance and Cancer 7, DOI 10.1007/978-1-4614-6819-6_2, © Springer Science+Business Media New York 2013 Abstract Infl ammasomes are a family of protein complexes that recognize diverse microbial and endogenous danger signals to promote innate immune responses, tissue infl ammation and injury, or cell death via pyroptosis. Infl ammasome activation results in the recruitment and activation of caspase-1, which is required for the production of the proinfl ammatory cytokines interleukin-1β (IL-1β) and IL-18 that can modulate both adaptive and innate immune responses through effects on leukocyte survival, proliferation, differentiation, and migration. Recent studies suggest that infl ammasome activity may also play important roles in several nonmicrobial disease states associated with chronic infl ammation. For example, NLRP3 infl ammasome expression and IL-1β production are both increased in obesity, and recent work has implicated NLRP3 infl ammasome activation in a variety of obesity-linked conditions including gout, type 2 diabetes mellitus, metabolic liver disease, atherosclerosis, Alzheimer’s disease, cancer and rheumatoid arthritis. Further, many of the factors associated with these conditions, including elevated plasma glucose, fatty acids, uric acid and cholesterol crystals, and β-amyloid, have been shown to be elevated during obesity and to stimulate NLRP3 infl ammasome expression or activation. Since chronic NLRP3 activation appears to play important roles in several common disease states, better understanding of infl ammasome regulation and function may lead to better therapeutic approaches. Several agents that attenuate NLRP3 infl ammasome activity or inhibit its primary effector, IL-1β, are currently under development or in early clinical trials as therapeutics to treat these common disease Chapter 2 Infl ammasomes and Obesity